Blog

« Back to Blog

The US Oncology Network Announces New National Policy Board Chair, Mark Fleming, MD

Dr. Mark T. Fleming, a physician with Virginia Oncology Associates (VOA), a member of The US Oncology Network, has been named the new Chair of the National Policy Board (NPB)—the governing board comprised of physician and operational leaders that guides and leads the organization.

Elected by his or her peers, the NPB Chair serves as the voice for The Network physicians and works closely with the President and Chief Medical Officer to ensure alignment across the organization’s strategic initiatives during their three-year term. Starting on October 1, 2021, Dr. Fleming will fill the shoes of Lucy Langer, MD, who served as NBP Chair for the past six years with two consecutive terms.

A Strong Medical Background
Dr. Fleming is a board-certified medical oncologist with VOA. He received his medical degree from Medical University of Ohio prior to completing his residency at Temple University Hospital in Philadelphia, PA, and his Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY.

A member of the NPB for the past two years, Dr. Fleming also serves as the medical director of The Network’s Genitourinary (bladder, kidney, prostate and testicular cancers) Research Committee. He is a passionate speaker on the importance of cancer education and the early detection of prostate cancer.

“With the selection of Dr. Fleming as NPB Chair, we are reaffirming our commitment to being a physician-led organization that champions community oncology,” said Jason Hammonds, president of The Network. “Physicians have a voice in every aspect of our organization, from our governing board to the various committees that lead and guide us. I look forward to working closely with Dr. Fleming as we continue our goal of advancing high-quality cancer care and improving outcomes for patients across the country.”

Dynamic, Impactful Leadership
Informing the decision-making process for the organization at every level, the NPB—made up of practice presidents, operational leaders and dozens of committee leaders—is critical to The Network’s success.

“A respected leader in the medical community, Dr. Fleming is a perfect fit for the role of NPB Chair,” said Marcus Neubauer, MD, chief medical officer of The Network. “I look forward to working with Mark on a range of initiatives important to community oncology practices, from operational matters, clinical research, pharmacy and therapeutics, cancer center workflows, staff diversity and inclusion and more. These are exciting times for oncology with promising new treatments coming to the fore, and I know that Dr. Fleming will help lead us into a bright future.”